Last reviewed · How we verify
MAT2203
MAT2203 is a lipid nanoparticle formulation of amphotericin B designed to improve drug delivery and reduce toxicity in fungal infections.
MAT2203 is a lipid nanoparticle formulation of amphotericin B designed to improve drug delivery and reduce toxicity in fungal infections. Used for Invasive fungal infections (including aspergillosis and candidiasis), Cryptococcal meningitis.
At a glance
| Generic name | MAT2203 |
|---|---|
| Also known as | oral amphotericin B, cAMB |
| Sponsor | Matinas BioPharma Nanotechnologies, Inc. |
| Drug class | Antifungal agent (lipid nanoparticle formulation) |
| Target | Fungal cell membrane ergosterol |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MAT2203 encapsulates amphotericin B, a polyene antifungal agent, within proprietary lipid nanoparticles to enhance bioavailability and reduce nephrotoxicity and infusion-related reactions associated with conventional amphotericin B formulations. The nanoparticle delivery system allows for improved targeting to fungal pathogens while minimizing exposure to healthy tissues.
Approved indications
- Invasive fungal infections (including aspergillosis and candidiasis)
- Cryptococcal meningitis
Common side effects
- Nephrotoxicity
- Infusion-related reactions
- Hypokalemia
- Anemia
Key clinical trials
- CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis (PHASE2)
- Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) (PHASE1, PHASE2)
- Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 (PHASE3)
- Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia (PHASE2)
- Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis (PHASE2)
- Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection (PHASE1, PHASE2)
- Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAT2203 CI brief — competitive landscape report
- MAT2203 updates RSS · CI watch RSS
- Matinas BioPharma Nanotechnologies, Inc. portfolio CI